**Sunday, April 23**

|  |  |
| --- | --- |
|   |   |
|   | 08:30-10:00, Main Auditorium |
|   | **Clinical Focus Session** |
| **CF 101** | **Colorectal cancer patients – the challenge** |
|   |   |
|   | *Moderators: A. Cervantes (Valencia/ES), A. Gangi (Strasbourg/FR)* |
|   |   |
| 101.1 101.2 101.3 101.4101.5 101.6  | Demographics and need for treatment*A. Cervantes (Valencia/ES)*Treatment strategies according to the new ESMO guidelines*D. Arnold (Lisbon/PT)*Who is the ideal candidate for liver surgery?*to be announced*Invited scientific paperLocal ablation in oligometastatic disease*A. Gillams (London/UK)*Intra-arterial therapies in advanced metastases*P.L. Pereira (Heilbronn/DE)* |
|   |   |
|   |   |
|   | 10:30-12:00, Auditorium 2 |
|   | **Clinical Focus Session** |
| **CF 201** | **Immunotherapy for cancer** |
|   |   |
|   | *Moderators: J.-F.H. Geschwind (New Haven, CT/US), P. Sarobe (Pamplona/ES)* |
|   |   |
| 201.1 201.2 201.3 201.4 201.5  | Cancer and immune reaction*J.J. Lasarte (Pamplona/ES)*Immunoscore: is it more relevant than TNM?*J. Rodríguez (Pamplona/ES)*Checkpoint inhibitors*M. Fuchs (Munich/DE)*Tumour exosomes – determination of organotropic metastases*B. Costa-Silva (Lisbon/PT)*IO and immunotherapy in cancer*J.P. Erinjeri (New York, NY/US)* |
|   |   |
|   |   |
|   | 10:30-12:00, Main Auditorium |
|   | **Clinical Focus Session** |
| **CF 202** | **Colorectal cancer and IO: where is the evidence?** |
|   |   |
|   | *Moderator: P. Gibbs (Melbourne, VIC/AU)* |
|   |   |
| 202.1 202.2 202.3 202.4 202.5  | CLOCC trial in detail*O.M. van Delden (Amsterdam/NL)*Evidence for surgery as a curative treatment*A. Denys (Lausanne/CH)*SIRFLOX trial in detail*P. Gibbs (Melbourne, VIC/AU)*Does progression-free survival translate into overall survival?*R. Sharma (London/UK)*Evidence in endpoints for IO in CRC mets*R. Salem (Chicago, IL/US)* |
|   |   |
|   |   |
|   | 10:30-12:00, HDT Room |
|   | **Hands-on Device Training** |
| **TA-HDT 1** | **Tumour ablation – Radiofrequency** |
|   |   |
|   | [*Please click here for further details.*](http://www.ecio.org/index.php?pid=133) |
|   |   |
|   |   |
|   | 13:00-14:30 |
|   | **Satellite Symposia** |
|   |   |
|   |   |
|   | 15:00-16:30, Main Auditorium |
|   | **Multidisciplinary Tumour Board** |
| **MTB 401** | **CRC metastases – beyond the guidelines** |
|   |   |
|   | *Coordinator: T.K. Helmberger (Munich/DE)* |
|   |   |
|   | *Panellists: D.J. Breen (Southampton/UK), A. Cervantes (Valencia/ES),**T. de Baère (Villejuif/FR), C.R. Ferrone (Boston, MA/US)* |
|   |   |
|   |   |
|   | 15:00-16:30, Auditorium 2 |
|   | **Technical Focus Session** |
| **TF 402** | **Cutting-edge developments** |
|   |   |
|   | *Moderators: K. Malagari (Athens/GR), J. Ricke (Magdeburg/DE)* |
|   |   |
| 402.1 402.2 402.3 402.4402.5 402.6  | Drug-eluting particles*R. Duran (Lausanne/CH)*Thermal ablation*L. Crocetti (Pisa/IT)*Radioembolisation*M. van den Bosch (Utrecht/NL)*Invited scientific paperIntratumoural immunotherapy and viral therapy*L. Tselikas (Villejuif/FR)*Immunotherapy plus ablation or DEB-TACE*B.J. Wood (Bethesda, MD/US)* |
|   |   |
|   |   |
|   | 15:00-16:30, HDT Room |
|   | **Hands-on Device Training** |
| **TA-HDT 2** | **Tumour ablation – Radiofrequency** |
|   |   |
|   | [*Please click here for further details.*](http://www.ecio.org/index.php?pid=133) |
|   |   |
|   |   |
|   | 17:00-18:30, Main Auditorium |
|   | **Clinical Focus Session** |
| **CF 501** | **Follow the colorectal cancer patients: quality and efficacy** |
|   |   |
|   | *Moderators: A. Adam (London/UK), B. Gebauer (Berlin/DE)* |
|   |   |
| 501.1 501.2 501.3 501.4 501.5  | What are the guidelines?*R. Vera (Pamplona/ES)*Does expensive and short-term imaging follow-up affect the outcome?*R.G.H. Beets-Tan (Amsterdam/NL)*PET-CT: a critical review*N. Schäfer (Lausanne/CH)*PRO, PCO and PREM – what do they tell us?*P. Reimer (Karlsruhe/DE)*Changing healthcare systems: what are convincing outcome measures?*I. Durand-Zaleski (Paris/FR)* |
|   |   |
|   |   |
|   | 17:00-18:30, Auditorium 2 |
|   | **Clinical Focus Session** |
| **CF 502** | **Getting IO into practice** |
|   |   |
|   | *Moderators: J. Lammer (Vienna/AT), R.A. Morgan (London/UK)* |
|   |   |
| 502.1 502.2 502.3 502.4 502.5  | Curriculum in IO*P.P. Rao (Dombivli/IN)*How to increase patient referral*T.F. Jakobs (Munich/DE)*Patient pathway in IO*J. Ricke (Magdeburg/DE)*Interaction with other disciplines*J.I. Bilbao (Pamplona/ES)*How do I promote IO services to my administration?*R.-T. Hoffmann (Dresden/DE)* |
|   |   |
|   |   |
|   | 18:30-19:00 |
|   | **Satellite Symposia** |
|   |   |

TOP

**Monday, April 24**

|  |  |
| --- | --- |
|   |   |
|   | 07:45-08:15 |
|   | **Satellite Symposia** |
|   |   |
|   |   |
|   | 08:30-10:00, Main Auditorium |
|   | **Clinical Focus Session** |
| **CF 801** | **Lung metastases** |
|   |   |
|   | *Moderators: A. Gillams (London/UK), U. Martens (Heilbronn/DE)* |
|   |   |
| 801.1 801.2 801.3801.4 801.5 801.6 | Rationale for local treatment – does it help patients?*I. Gil-Bazo (Pamplona/ES)*Resection – current status and evidence*T. Treasure (London/UK)*Invited scientific paperSBRT – current status and evidence*L.M. Kenny (Brisbane, QLD/AU)*Thermal ablation – current status and evidence*T. de Baère (Villejuif/FR)*Round-table discussion |
|   |   |
|   |   |
|   | 08:30-10:00, Auditorium 2 |
|   | **Clinical Focus Session** |
| **CF 802** | **Understanding tumour biology** |
|   |   |
|   | *Moderators: P. Gibbs (Melbourne, VIC/AU), N. Goldberg (Jerusalem/IL)* |
|   |   |
| 802.1 802.2 802.3 802.4 802.5  | Hypoxia and anoxia – friend or enemy?*B.J. Wood (Bethesda, MD/US)*IO procedures inducing tumour spread*C.T. Sofocleous (New York, NY/US)*Post-ablation inflammation and immune reactions – the bad*N. Goldberg (Jerusalem/IL)*Post-ablation inflammation and immune reactions – the good*M.H.M.G.M. den Brok (Nijmegen/NL)*Combined locoregional and systemic immunotherapy*L. Tselikas (Villejuif/FR)* |
|   |   |
|   |   |
|   | 10:30-11:30, Main Auditorium |
| **HL 901** | **Honorary Lecture** |
|   |   |
|   | *Moderators: J.I. Bilbao (Pamplona/ES), E. Brountzos (Athens/GR)* |
|   |   |
|   | *Laudation: A. Gangi (Strasbourg/FR)* |
|   |   |
| 901.1   | Metastatic colorectal cancer and percutaneous thermal ablation:a happy marriage?*J. Palussière (Bordeaux/FR)* |
|   |   |
|   |   |
|   | 10:30-12:00, HDT Room |
|   | **Hands-on Device Training** |
| **TA-HDT 3** | **Tumour ablation – Microwave** |
|   |   |
|   | [*Please click here for further details.*](http://www.ecio.org/index.php?pid=133) |
|   |   |
|   |   |
|   | 11:30-12:00, Main Auditorium |
|   | **Paper Session** |
| **PS 902** | **The best IO papers of 2016** |
|   |   |
|   | *Moderators: J.I. Bilbao (Pamplona/ES), E. Brountzos (Athens/GR)* |
|   |   |
| 902.1 | Yttrium-90 radioembolization for colorectal cancer liver metastases: a prospective cohort study on circulating angiogenic factors and treatment response*C.E.N.M. Rosenbaum, A.F. van den Hoven, M.N.G.J.A. Braat, M. Koopman,**M.G.E.H. Lam, B.A. Zonnenberg, H.M. Verkooijen, M.A.A.J. van den Bosch;**Utrecht/NL* |
| 902.2 | Independent analysis of albumin-bilirubin grade in a 765-patient cohort treated with transarterial locoregional therapy for hepatocellular carcinoma*R. Hickey, S. Mouli, L. Kulik, K. Desai, B. Thornburg, D. Ganger, T. Baker,**M. Abecassis, J. Ralph Kallini, A. Gabr, V.L. Gates, A.B. Benson III,**R.J. Lewandowski, R. Salem; Chicago, IL/US* |
| 902.3 | Pharmacokinetics, safety, and efficacy of chemoembolization with doxorubicin-loaded tightly calibrated small microspheres in patients with hepatocellular carcinoma*K. Malagari, T. Kiakidis, M. Pomoni, H. Moschouris, E. Emmanouil,**T. Spiridopoulos, V. Sotirchos, S. Tandeles, D. Koundouras, A. Kelekis,**D. Filippiadis, A. Charokopakis, E. Bouma, A. Chatziioannou, S. Dourakis,**J. Koskinas, T. Karampelas, K. Tamvakopoulos, N. Kelekis, D. Kelekis;**Athens/GR* |
|   |   |
|   |   |
|   | 13:00-14:30 |
|   | **Satellite Symposia** |
|   |   |
|   |   |
|   | 15:00-16:30, Auditorium 2 |
|   | **Multidisciplinary Tumour Board** |
| **MTB 1101** | **Lung tumours – beyond the guidelines** |
|   |   |
|   | *Coordinator: J. Palussière (Bordeaux/FR)* |
|   |   |
|   | *Panellists: J. Aristu (Pamplona/ES), A. Gillams (London/UK),**J. Jougon (Pessac/FR), U. Martens (Heilbronn/DE)* |
|   |   |
|   |   |
|   | 15:00-16:30, Main Auditorium |
|   | **Clinical Focus Session** |
| **CF 1102** | **IO in HCC: early and intermediate** |
|   |   |
|   | *Moderators: R. Golfieri (Bologna/IT), B. Sangro (Pamplona/ES)* |
|   |   |
| 1102.1 1102.2 1102.3 1102.4 1102.5  | From Barcelona to Hong Kong: the HCC classifications*B. Sangro (Pamplona/ES)*What to do when on the waiting list for transplantation*V. Mazzaferro (Milan/IT)*Local ablation in early stage: do we compete with surgery?*L. Crocetti (Pisa/IT)*Intermediate stage: is there room for radioembolisation?*R. Salem (Chicago, IL/US)*Intermediate stage: what are the indications for combined therapy?*T.F. Jakobs (Munich/DE)* |
|   |   |
|   |   |
|   | 15:00-16:30, HDT Room |
|   | **Hands-on Device Training** |
| **TA-HDT 4** | **Tumour ablation – Microwave** |
|   |   |
|   | [*Please click here for further details.*](http://www.ecio.org/index.php?pid=133) |
|   |   |
|   |   |
|   | 17:00-18:30, Main Auditorium |
|   | **Clinical Focus Session** |
| **CF 1201** | **IO in HCC: what's new?** |
|   |   |
|   | *Moderators: V. Mazzaferro (Milan/IT), J. Urbano (Madrid/ES)* |
|   |   |
| 1201.1 1201.2 1201.3 1201.4 1201.5 1201.6 1201.7  | Current status of classifying HCC and tailoring therapy: an update*J.-F.H. Geschwind (New Haven, CT/US)*New drugs in advanced HCC*B. Sangro (Pamplona/ES)*Bland embolisation vs. drug-eluting beads: the evidence*K. Malagari (Athens/GR)*RF vs. microwave in tumours up to 4 cm: the evidence*A. Denys (Lausanne/CH)*Cryoablation vs. RF*P.B. Shyn (Boston, MA/US)*SARAH trial*V. Vilgrain (Clichy/FR)*Idarubicin TACE*B. Guiu (Montpellier/FR)* |
|   |   |
|   |   |
|   | 17:00-18:30, Auditorium 2 |
|   | **Clinical Focus Session** |
| **CF 1202** | **Primary lung cancer** |
|   |   |
|   | *Moderators: G. Bastarrika (Pamplona/ES), J. Palussière (Bordeaux/FR)* |
|   |   |
| 1202.1 1202.2  1202.31202.4 1202.5 1202.6  | An update of systemic therapy of NSCLC*U. Martens (Heilbronn/DE)*Surgery, SBRT, local ablation: an appraisal of the pre- and post-treatmentlung function*E. Quoix (Strasbourg/FR)*Invited scientific paperSBRT*J. Aristu (Pamplona/ES)*Local ablation*X. Buy (Bordeaux/FR)*Imaging follow-up of SBRT and ablation*R.D. Suh (Los Angeles, CA/US)* |
|   |   |
|   |   |
|   | 18:30-19:00 |
|   | **Satellite Symposia** |
|   |   |

TOP

**Tuesday, April 25**

|  |  |
| --- | --- |
|   |   |
|   | 07:45-08:15 |
|   | **Satellite Symposia** |
|   |   |
|   |   |
|   | 08:30-10:00, Auditorium 2 |
|   | **Clinical Focus Session** |
| **CF 1501** | **Breast cancer patients – the IO add-on** |
|   |   |
|   | *Moderators: E. Aranda (Córdoba/ES), F. Orsi (Milan/IT)* |
|   |   |
| 1501.1 1501.2 1501.3 1501.41501.5 1501.6  | Demographics and need for treatment*A. Urrutikoetxea (San Sebastián/ES)*Local treatment in metastatic breast cancer: the oncologist's perspective*J.-E. Kurtz (Strasbourg/FR)*Ablation of breast tumours*J. Palussière (Bordeaux/FR)*Invited scientific paperIO in metastatic liver disease*F. Orsi (Milan/IT)*IO in metastatic bone disease*D.K. Filippiadis (Athens/GR)* |
|   |   |
|   |   |
|   | 08:30-10:00, Main Auditorium |
|   | **Video Learning Session** |
| **VL 1502** | **How I do it – lung, kidney, bone** |
|   |   |
|   | *Moderators: X. Serrés (Barcelona/ES)**Commentator: D.J. Breen (Southampton/UK)* |
|   |   |
| 1502.1 1502.2 1502.3 1502.4  | Lung cryoablation*F. Deschamps (Villejuif/FR)*Kidney microwave ablation*J.L. Hinshaw (Madison, WI/US)*Bone consolidation*J. Garnon (Strasbourg/FR)*Thyroid radiofrequency ablation*F. Stacul (Trieste/IT)* |
|   |   |
|   |   |
|   | 10:30-12:00, Auditorium 2 |
|   | **Clinical Focus Session** |
| **CF 1601** | **MSK tumours beyond the spine** |
|   |   |
|   | *Moderators: M.R. Callstrom (Rochester, MN/US), A.D. Kelekis (Athens/GR)* |
|   |   |
| 1601.1 1601.2 1601.31601.4 1601.5 1601.6  | Bone consolidation in cancer patients: biomechanical and surgical*P.J. Papagelopoulos (Athens/GR)*Indications and limits of SBRT*S. Myrehaug (Toronto, ON/CA)*Invited scientific paperAblation and consolidation*R.-T. Hoffmann (Dresden/DE)*Management of benign bone tumours excluding osteoid osteoma*J. Jennings (St. Louis, MO/US)*Treatment options for soft tissue tumours*X. Buy (Bordeaux/FR)* |
|   |   |
|   |   |
|   | 10:30-12:00, Main Auditorium |
|   | **Clinical Focus Session** |
| **CF 1602** | **Complication management** |
|   |   |
|   | *Moderators: P. Reimer (Karlsruhe/DE), O.M. van Delden (Amsterdam/NL)* |
|   |   |
| 1602.1 1602.2 1602.3 1602.4 1602.5 1602.6  | Liver thermal ablation*L. Solbiati (Rozzano/IT)*TACE*Y. Arai (Tokyo/JP)*Radioembolisation*B. Peynircioglu (Ankara/TR)*Kidney cryoablation*D.J. Breen (Southampton/UK)*Lung ablation*R.D. Suh (Los Angeles, CA/US)*Bone ablation*J. Garnon (Strasbourg/FR)* |
|   |   |
|   |   |
|   | 10:30-12:00, HDT Room |
|   | **Hands-on Device Training** |
| **TA-HDT 5** | **Tumour ablation – Alternative techniques and image guidance** |
|   |   |
|   | [*Please click here for further details.*](http://www.ecio.org/index.php?pid=133) |
|   |   |
|   |   |
|   | 13:00-14:30 |
|   | **Satellite Symposia** |
|   |   |
|   |   |
|   | 15:00-16:30, Auditorium 2 |
|   | **Clinical Focus Session** |
| **CF 1801** | **Genomics in cancer** |
|   |   |
|   | *Moderators: B. Costa-Silva (Lisbon/PT), R. Lencioni (Miami, FL/US)* |
|   |   |
| 1801.1 1801.2 1801.3 1801.4 1801.5  | Genomics – a general concept?*R.B. Corcoran (Boston, MA/US)*Is genomics changing the percutaneous biopsy business?*G. Frija (Paris/FR)*Radiomics in MRI*D. Bonekamp (Heidelberg/DE)*Radiomics – new markers in PET-CT*N. Schäfer (Lausanne/CH)*Iomics – what could it mean?*R. Lencioni (Miami, FL/US)* |
|   |   |
|   |   |
|   | 15:00-16:30, Main Auditorium |
|   | **Video Learning Session** |
| **VL 1802** | **How I do it – liver** |
|   |   |
|   | *Moderator: A. Denys (Lausanne/CH)**Commentator: P.E. Huppert (Darmstadt/DE)* |
|   |   |
| 1802.1 1802.2 1802.3 1802.4 1802.5  | Complex liver thermal ablation*P. Chevallier (Nice/FR)*Liver DEB-TACE*R. Golfieri (Bologna/IT)*Liver balloon TACE*T. de Baère (Villejuif/FR)*Liver radioembolisation*P. Reimer (Karlsruhe/DE)*Portal vein and hepatic vein embolisation*R. Duran (Lausanne/CH)* |
|   |   |
|   |   |
|   | 17:00-18:30, Main Auditorium |
|   | **Clinical Focus Session** |
| **CF 1901** | **Spinal tumours** |
|   |   |
|   | *Moderators: A. Gangi (Strasbourg/FR), J.W. Jennings (Saint Louis, MO/US)* |
|   |   |
| 1901.1 1901.2 1901.31901.4 1901.5 1901.6  | Spinal surgery in cancer patients*J.-P. Steib (Strasbourg/FR)*Indications and limits of SBRT*L.M. Kenny (Brisbane, QLD/AU)*Invited scientific paperAblation and augmentation*J. Jennings (St. Louis, MO/US)*Management of benign tumours*A.D. Kelekis (Athens/GR)*The role of embolisation*L. Hechelhammer (St. Gallen/CH)* |
|   |   |
|   |   |
|   | 17:00-18:30, Auditorium 2 |
|   | **Clinical Focus Session** |
| **CF 1902** | **Promoting IO evidence** |
|   |   |
|   | *Moderators: L. Donoso (Barcelona/ES), P.L. Pereira (Heilbronn/DE)* |
|   |   |
| 1902.1 1902.2 1902.3 1902.4 1902.5  | CIRT*J.I. Bilbao (Pamplona/ES)*CIREL*P.L. Pereira (Heilbronn/DE)*Overview ongoing studies*V. Vilgrain (Clichy/FR)*How to bring a product to market?*N.T. Lange (Bonn/DE)*The value of registries vs. randomised trials*G.J. Poston (Liverpool/UK)* |
|   |   |
|   |   |
|   | 18:30-19:00 |
|   | **Satellite Symposia** |
|   |   |

TOP

**Wednesday, April 26**

|  |  |
| --- | --- |
|   |   |
|   | 08:30-10:00, Main Auditorium |
|   | **Clinical Focus Session** |
| **CF 2101** | **Kidney tumours** |
|   |   |
|   | *Moderators: J.C. Durack (New York, NY/US), D.K. Filippiadis (Athens/GR)* |
|   |   |
| 2101.1 2101.2 2101.3 2101.4 2101.5  | Demographics and need for treatment*J.E. Robles (Pamplona/ES)*Evidence-based nephron-sparing surgery*B.W. Lagerveld (Amsterdam/NL)*Evidence-based ablation vs. resection outcomes*D.J. Breen (Southampton/UK)*Palliative intervention in metastatic renal tumours*M.R. Callstrom (Rochester, MN/US)*The CIRSE SOP paper on RCC (cT1a)*M.E. Krokidis (Cambridge/UK)* |
|   |   |
|   |   |
|   | 08:30-10:00, Auditorium 2 |
|   | **Clinical Focus Session** |
| **CF 2102** | **Recipes for general patient management** |
|   |   |
|   | *Moderators: P.E. Bize (Genolier/CH), F. Orsi (Milan/IT)* |
|   |   |
| 2102.1 2102.2 2102.3 2102.4 2102.5 2102.6  | Assessing the patient's general condition*M. Fuchs (Munich/DE)*Analgosedation vs. ITN*R. Bale (Innsbruck/AT)*Peri-interventional pain management*A. Vari (Rome/IT)*Peri-interventional antibiotics*G. Maleux (Leuven/BE)*Anticoagulation and anti-aggregants: how to deal with them*J.A. Páramo (Pamplona/ES)*Postembolisation syndrome management*B. Gebauer (Berlin/DE)* |
|   |   |
|   |   |
|   | 10:00-10:45 |
|   | **Satellite Symposium** |
|   |   |
|   |   |
|   | 11:15-12:45, Main Auditorium |
| **MM 2201** | **Morbidity & Mortality Conference** |
|   |   |
|   | *Coordinators: M. Burrel (Barcelona/ES), P. Chevallier (Nice/FR)* |
|   |  |